Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K203193
    Date Cleared
    2021-03-04

    (127 days)

    Product Code
    Regulation Number
    880.5570
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The BD Intraosseous Infusion System provides intraosseous access in the proximal tibia, distal tibia and humeral head (proximal humerus) of adult and pediatric patients, and the distal femur in pediatric patients when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases for up to 24 hours.

    Device Description

    The BD Intraosseous Infusion System provides clinicians and emergency personnel with access to the intraosseous space for resuscitation and lifesaving fluid delivery for up to 24 hours. The BD Intraosseous Infusion System consists of the following: a single use hypodermic needle (with needle safety cap), a powered or manual driver to assist with needle insertion, an extension set, and; an adhesive-backed securement dressing. For insertions using the powered driver, the hypodermic needle includes a needle hub that mates with a stylet connected to a drive adapter hub. The drive adapter hub includes a magnetic insert that attaches to the powered driver prior to needle insertion. The BD Intraosseous Infusion System is an easy-grip, hand-held, battery-powered device with a rechargeable lithium battery used to assist in the insertion of the subject device needle through the bone cortex. The assembly of the hypodermic needle and stylet with connected drive adapter hub is referred to as the needle set. For insertions using the manual driver, the needle and the needle hub mate with a stylet in the same way as the needle set that is used with the powered driver, except the stylet is integrated into the handle of the manual driver instead of a drive adaptor hub (i.e. the manual driver needle assembly does not include a drive adapter hub). The stylet was designed to include a passive safety feature to protect the placer from sharps injury. After the needle is inserted, the stylet is separated from the needle and needle hub. Upon separation of the stylet from the needle hub, the passive safety feature is released onto the stylet tip and can be safely discarded into a sharps container. Following needle insertion, the securement dressing can be applied to secure the needle hub to the skin. An extension set is available for access to the needle hub to support fluid exchange. The subject device BD Intraosseous Infusion System will be offered in needle set (for use with the powered driver) and manual driver needle kit configurations. Each kit configuration will include a securement dressing and an extension set.

    AI/ML Overview

    The provided text describes the BD Intraosseous Infusion System and its substantial equivalence to a predicate device, the Piper GO-IO® Intraosseous Infusion System. It outlines various performance, sterilization, packaging, and biocompatibility tests conducted to demonstrate the device meets acceptance criteria.

    Here's a breakdown of the requested information based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    The document lists numerous performance tests and standards followed for both the Needle Set Kit and Manual Driver Kit configurations of the BD Intraosseous Infusion System. While specific numerical acceptance criteria and detailed performance results are not explicitly stated in a quantified manner for each test, the general reporting indicates that the device met all predetermined acceptance criteria.

    Acceptance Criteria (Test Category)Standard Followed / Test ConductedReported Device Performance
    Needle Set Kit and Manual Driver Kit Performance Tests
    Needle Outer Diameter (OD)ISO 9626: 2016 and Internal Protocol/StandardMet predetermined acceptance criteria
    Needle LengthInternal Protocol/StandardMet predetermined acceptance criteria
    Needle LubricityISO 7864: 2016Met predetermined acceptance criteria
    Needle Quality, Surface Finish, and CleanlinessISO 9626: 2016Met predetermined acceptance criteria
    Needle to Hub Assembly TensileInternal Protocol/StandardMet predetermined acceptance criteria
    Stylet to Drive Adapter Hub TensileInternal Protocol/StandardMet predetermined acceptance criteria
    Needle and Stylet Disassembly ForceInternal Protocol/StandardMet predetermined acceptance criteria
    Safety ActivationFDA Guidance for Sharps Injury Prevention Features & ISO 23908: 2011Met predetermined acceptance criteria
    Stylet Safety Override (force to failure)ISO 23908: 2011Met predetermined acceptance criteria
    Manual Driver Hub to Stylet TensileInternal Protocol/StandardMet predetermined acceptance criteria
    Needle Resistance to CorrosionISO 9626: 2016Met predetermined acceptance criteria
    Needle Hub LuerISO 594-1: 1986 and ISO 594-2: 1998Met predetermined acceptance criteria
    Needle Hub CleanlinessISO 7864: 2016Met predetermined acceptance criteria
    Needle PointISO 7864: 2016Met predetermined acceptance criteria
    Needle Resistance to BreakageISO 9626: 2016Met predetermined acceptance criteria
    Needle StiffnessISO 9626: 2016 and Internal Protocol/StandardMet predetermined acceptance criteria
    Gravity Flow RateInternal Protocol/StandardMet predetermined acceptance criteria
    Liquid Leak Needle HubInternal Protocol/StandardMet predetermined acceptance criteria
    Limits for Acidity or Alkalinity (Needle)ISO 9626: 2016 / ISO 7864: 2016Met predetermined acceptance criteria
    Limits for Extractable Metals (Needle)ISO 7864: 2016Met predetermined acceptance criteria
    Depth MarkingsInternal Protocol/StandardMet predetermined acceptance criteria
    Insertion ForceInternal Protocol/StandardMet predetermined acceptance criteria
    Needle Bone Retention - Needle Point ODInternal Protocol/StandardMet predetermined acceptance criteria
    Packaging Integrity and Seal StrengthISO 11607-1:2006, ASTM F88/F88M: 2015, ASTM F1886/F1886M: 2016, ASTM F1929: 2015Met predetermined acceptance criteria
    Device Usability/Simulated UseInternal Protocol/StandardMet predetermined acceptance criteria
    Sharps Injury Prevention Feature (Simulated Clinical Use)FDA Guidance for Sharps Injury Prevention Features & ISO 23908: 2011Met predetermined acceptance criteria
    Sterilization, Packaging, and Shelf-Life
    Sterilization Validation/AdoptionISO 11135:2014Met predetermined acceptance criteria
    Packaging/Shelf-Life ValidationsISO 11607-1 AMD 1: 2014, ASTM F88/F88M: 2015, ASTM F1886/F1886M: 2016, ASTM F1929: 2015Met predetermined acceptance criteria
    Sterilant ResidualsISO 10993-7: 2008Met predetermined acceptance criteria
    Bacterial EndotoxinUSP , USPMet predetermined acceptance criteria
    Biocompatibility Evaluation
    CytotoxicityISO 10993-05: 2009Met predetermined acceptance criteria
    SensitizationISO 10993-10: 2010Met predetermined acceptance criteria
    Irritation/Intracutaneous ReactivityISO 10993-10: 2010 (Assumed, as it's listed under this section without a separate standard)Met predetermined acceptance criteria
    Acute Systemic ToxicityISO 10993-11: 2006Met predetermined acceptance criteria
    Material Mediated PyrogenicityISO 10993-11: 2006 (Assumed, as it's listed under this section without a separate standard)Met predetermined acceptance criteria
    HemocompatibilityISO 10993-4: 2017Met predetermined acceptance criteria

    2. Sample size used for the test set and the data provenance

    The document does not specify the exact sample sizes used for each individual performance or biological test. It generally refers to "performance (verification and validation testing)" and "biological tests."
    The data provenance is internal to the manufacturer ("Internal Protocol/Standard") or based on established industry standards (e.g., ISO, ASTM, FDA Guidance). The document does not specify country of origin for data or if it was retrospective or prospective, as this is a device submission focused on technical performance and safety rather than clinical trial data.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    This information is not provided in the document. The tests performed are primarily engineering and laboratory-based, adhering to established standards, rather than requiring expert consensus for a "ground truth" in a clinical sense. For "Device Usability/Simulated Use" and "Sharps Injury Prevention Feature (Simulated Clinical Use)" tests, it's implied that users were involved, but their qualifications and numbers are not detailed.

    4. Adjudication method for the test set

    This information is not provided in the document. Given the nature of the tests (physical, chemical, mechanical, and biological properties according to standards), adjudication methods typically used for subjective clinical assessments are not relevant here.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    This information is not applicable and therefore not provided. The BD Intraosseous Infusion System is a physical medical device (needle, driver, etc.) for infusion access, not an AI-powered diagnostic or assistive technology that would involve human "readers" or an AI component.

    6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

    This information is not applicable and therefore not provided. The device is not an algorithm or software-only system.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

    For the technical and biological tests, the "ground truth" is defined by the established criteria within the referenced ISO, ASTM standards, FDA guidance, and internal protocols. These standards define acceptable ranges, material properties, and performance limits. For "Device Usability/Simulated Use" and "Sharps Injury Prevention Feature (Simulated Clinical Use)", the ground truth would be successful completion of tasks and demonstration of safety features as per pre-defined objectives. There is no mention of expert consensus, pathology, or outcomes data to establish ground truth in this submission.

    8. The sample size for the training set

    This information is not applicable and therefore not provided. This device does not use machine learning or AI, so there is no "training set."

    9. How the ground truth for the training set was established

    This information is not applicable and therefore not provided for the same reason as above.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1